Clinical grade ACE2 as a universal agent to block SARS‐CoV ‐2 variants
Abstract: The recent emergence of multiple SARS‐CoV‐2 variants has caused considerable concern due to both reduced vaccine efficacy and escape from neutralizing antibody therapeutics. It is, therefore, paramount to develop therapeutic strategies that inhibit all known and future SARS‐CoV‐2 variants. Here, we report that all SARS‐CoV‐2 variants analyzed, including variants of concern (VOC) Alpha, Beta, Gamma, Delta, and Omicron, exhibit enhanced binding affinity to clinical grade and phase 2 tested recombinant human soluble ACE2 (APN01). Importantly, soluble ACE2 neutralized infection of VeroE6 cells and human lung epithelial cells by all current VOC strains with markedly enhanced potency when compared to reference SARS‐CoV‐2 isolates. Effective inhibition of infections with SARS‐CoV‐2 variants was validated and confirmed in two independent laboratories. These data show that SARS‐CoV‐2 variants that have emerged around the world, including current VOC and several variants of interest, can be inhibited by soluble ACE2, providing proof of principle of a pan‐SARS‐CoV‐2 therapeutic.
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Clinical grade ACE2 as a universal agent to block SARS‐CoV ‐2 variants ; day:04 ; month:07 ; year:2022 ; extent:14
EMBO molecular medicine / European Molecular Biology Organization ; (04.07.2022) (gesamt 14)
- Creator
-
Monteil, Vanessa
Eaton, Brett
Postnikova, Elena
Murphy, Michael
Braunsfeld, Benedict
Crozier, Ian
Kricek, Franz
Niederhöfer, Janine
Schwarzböck, Alice
Breid, Helene
Devignot, Stephanie
Klingström, Jonas
Thålin, Charlotte
Kellner, Max J.
Christ, Wanda
Havervall, Sebastian
Mereiter, Stefan
Knapp, Sylvia
Sanchez Jimenez, Anna
Bugajska‐Schretter, Agnes
Dohnal, Alexander
Ruf, Christine
Gugenberger, Romana
Hagelkruys, Astrid
Montserrat, Nuria
Kozieradzki, Ivona
Hasan Ali, Omar
Stadlmann, Johannes
Holbrook, Michael R.
Schmaljohn, Connie
Oostenbrink, Chris
Shoemaker, Robert H.
Mirazimi, Ali
Wirnsberger, Gerald
Penninger, Josef Martin
- DOI
-
10.15252/emmm.202115230
- URN
-
urn:nbn:de:101:1-2022070415114520569475
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:31 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Monteil, Vanessa
- Eaton, Brett
- Postnikova, Elena
- Murphy, Michael
- Braunsfeld, Benedict
- Crozier, Ian
- Kricek, Franz
- Niederhöfer, Janine
- Schwarzböck, Alice
- Breid, Helene
- Devignot, Stephanie
- Klingström, Jonas
- Thålin, Charlotte
- Kellner, Max J.
- Christ, Wanda
- Havervall, Sebastian
- Mereiter, Stefan
- Knapp, Sylvia
- Sanchez Jimenez, Anna
- Bugajska‐Schretter, Agnes
- Dohnal, Alexander
- Ruf, Christine
- Gugenberger, Romana
- Hagelkruys, Astrid
- Montserrat, Nuria
- Kozieradzki, Ivona
- Hasan Ali, Omar
- Stadlmann, Johannes
- Holbrook, Michael R.
- Schmaljohn, Connie
- Oostenbrink, Chris
- Shoemaker, Robert H.
- Mirazimi, Ali
- Wirnsberger, Gerald
- Penninger, Josef Martin
Other Objects (12)
Structures of ACE2–SIT1 recognized by Omicron variants of SARS-CoV-2
Antibody Fc-binding profiles and ACE2 affinity to SARS-CoV-2 RBD variants
Analysis of ACE2 genetic variants in 131 Italian SARS-CoV-2-positive patients
Universal subunit vaccine protects against multiple SARS-CoV-2 variants and SARS-CoV
ACE2‐Variants Indicate Potential SARS‐CoV‐2‐Susceptibility in Animals: A Molecular Dynamics Study
An IgM-like inhalable ACE2 fusion protein broadly neutralizes SARS-CoV-2 variants
ACE2: the molecular doorway to SARS-CoV-2
Outsmarting SARS-CoV-2 by empowering a decoy ACE2
SARS‐CoV‐2 variants of concern elicit divergent early immune responses in hACE2 transgenic mice
Multimeric ACE2-IgM fusions as broadly active antivirals that potently neutralize SARS-CoV-2 variants
ACE2-EGFR-MAPK signaling contributes to SARS-CoV-2 infection
Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry
Structures of ACE2–SIT1 recognized by Omicron variants of SARS-CoV-2
Antibody Fc-binding profiles and ACE2 affinity to SARS-CoV-2 RBD variants
Analysis of ACE2 genetic variants in 131 Italian SARS-CoV-2-positive patients
Universal subunit vaccine protects against multiple SARS-CoV-2 variants and SARS-CoV
ACE2‐Variants Indicate Potential SARS‐CoV‐2‐Susceptibility in Animals: A Molecular Dynamics Study
An IgM-like inhalable ACE2 fusion protein broadly neutralizes SARS-CoV-2 variants
ACE2: the molecular doorway to SARS-CoV-2
Outsmarting SARS-CoV-2 by empowering a decoy ACE2
SARS‐CoV‐2 variants of concern elicit divergent early immune responses in hACE2 transgenic mice
Multimeric ACE2-IgM fusions as broadly active antivirals that potently neutralize SARS-CoV-2 variants
ACE2-EGFR-MAPK signaling contributes to SARS-CoV-2 infection
Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry
Structures of ACE2–SIT1 recognized by Omicron variants of SARS-CoV-2
Antibody Fc-binding profiles and ACE2 affinity to SARS-CoV-2 RBD variants
Analysis of ACE2 genetic variants in 131 Italian SARS-CoV-2-positive patients
Universal subunit vaccine protects against multiple SARS-CoV-2 variants and SARS-CoV
ACE2‐Variants Indicate Potential SARS‐CoV‐2‐Susceptibility in Animals: A Molecular Dynamics Study
An IgM-like inhalable ACE2 fusion protein broadly neutralizes SARS-CoV-2 variants
ACE2: the molecular doorway to SARS-CoV-2
Outsmarting SARS-CoV-2 by empowering a decoy ACE2
SARS‐CoV‐2 variants of concern elicit divergent early immune responses in hACE2 transgenic mice
Multimeric ACE2-IgM fusions as broadly active antivirals that potently neutralize SARS-CoV-2 variants
ACE2-EGFR-MAPK signaling contributes to SARS-CoV-2 infection